Literature DB >> 22362679

The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK.

S McCormack1, S Fidler, M Fisher.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22362679     DOI： 10.1258/ijsa.2011.051211

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN： 0956-4624            Impact factor:   1.359


× No keyword cloud information.
  17 in total

1.  Provider attitudes toward oral preexposure prophylaxis for HIV prevention among high-risk men who have sex with men in Lima, Peru.

Authors:  Eric C Tang; Magdalena E Sobieszczyk; Eileen Shu; Pedro Gonzales; Jorge Sanchez; Javier R Lama
Journal:  AIDS Res Hum Retroviruses       Date:  2014-01-20       Impact factor: 2.205

Review 2.  Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

3.  HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial.

Authors:  Nigel J Garrett; Lise Werner; Nivashnee Naicker; Vivek Naranbhai; Sengeziwe Sibeko; Natasha Samsunder; Clive Gray; Carolyn Williamson; Lynn Morris; Quarraisha Abdool-Karim; Salim S Abdool-Karim
Journal:  J Acquir Immune Defic Syndr       Date:  2015-01-01       Impact factor: 3.731

4.  The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study.

Authors:  Gabriela B Gomez; Annick Borquez; Carlos F Caceres; Eddy R Segura; Robert M Grant; Geoff P Garnett; Timothy B Hallett
Journal:  PLoS Med       Date:  2012-10-09       Impact factor: 11.069

5.  Attitude towards antiretroviral Pre-Exposure Prophylaxis (PrEP) prescription among HIV specialists.

Authors:  Vincenzo Puro; Antonio Palummieri; Gabriella De Carli; Pierluca Piselli; Giuseppe Ippolito
Journal:  BMC Infect Dis       Date:  2013-05-14       Impact factor: 3.090

Review 6.  The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies.

Authors:  Gabriela B Gomez; Annick Borquez; Kelsey K Case; Ana Wheelock; Anna Vassall; Catherine Hankins
Journal:  PLoS Med       Date:  2013-03-12       Impact factor: 11.069

7.  Awareness and willingness to use HIV pre-exposure prophylaxis amongst gay and bisexual men in Scotland: implications for biomedical HIV prevention.

Authors:  Ingrid Young; Jessica Li; Lisa McDaid
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

Review 8.  Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe?

Authors:  Jean-Michel Molina; Claire Pintado; Caroline Gatey; Diane Ponscarme; Pierre Charbonneau; Benedicte Loze; Willy Rozenbaum; Constance Delaugerre
Journal:  BMC Med       Date:  2013-08-23       Impact factor: 8.775

Review 9.  How acceptable are antiretrovirals for the prevention of sexually transmitted HIV?: A review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention.

Authors:  Ingrid Young; Lisa McDaid
Journal:  AIDS Behav       Date:  2014-02

Review 10.  The European preexposure prophylaxis revolution.

Authors:  Gus Cairns; Sheena McCormack; Jean-Michel Molina
Journal:  Curr Opin HIV AIDS       Date:  2016-01       Impact factor: 4.283
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.